GLP-1 Drugs in Teenagers: What 18 Trials Show

The evidence for GLP-1 drugs in children and adolescents now runs to 18 randomized trials and 1,402 participants, and the results are consistently positive across every metabolic measure.^[1] Two numbers deserve to sit beside them: mean weight loss was 3.02 kg, and the median treatment duration across all those trials was half a year.

What the trials found

Every one of those is a real improvement with a confidence interval clear of zero. Gastrointestinal adverse events increased, which is expected. And on the outcome that frightens parents most — suicidal ideation or behaviors — there was no significant difference.^[1]

The weight number is much smaller than adults see

Three kilos is not what most people expect from a class of drugs discussed in terms of losing a fifth of your body weight. The gap has explanations — the pooled trials include older and weaker drugs alongside newer ones, follow-up is short, and a growing child’s weight is not a fixed target the way an adult’s is, which is why BMI percentile and BMI standard deviation score are the more meaningful rows.

A parent who has read about adults losing forty pounds is not being told the same thing by this evidence.

That does not make the result unimportant. A 7.24 percentile drop in BMI and a blood pressure reduction in a thirteen-year-old are meaningful over a lifetime. It does mean expectations set by adult coverage are the wrong expectations.

Six months is the whole evidence base

The median treatment duration across these trials was 0.51 years, with an interquartile range of three months to one year.^[1] This matters more here than in almost any other population.

• A child starting at 13 could be on treatment for decades. Six months of evidence against that is a very short lever.
• Puberty is a developmental window, and effects on growth, bone accrual and pubertal timing need years to observe, not months.
• The reassuring psychiatric finding carries the same limit. The authors say so directly — the data covered a relatively short follow-up.
• Nothing here speaks to what happens on stopping, which in adults means most of the weight returning. In a growing child that question has no adult analog at all.

One thing worth adding to that list: a separate analysis of STEP TEENS reports what happened to insulin resistance, liver enzymes and lipids in the same participants — what changed in the teenagers’ bloodwork. Those results are encouraging and every one of them is a surrogate marker.

What a parent should ask

1. Which drug, and is it approved for this age? Approval in adolescents is drug-specific and narrower than adult approval.
2. What is being measured? BMI percentile and standard deviation score describe a growing child; kilograms do not.
3. What is the plan for stopping, or not stopping? Ask it at the start rather than at year three.
4. Who is monitoring growth and puberty? This belongs with a pediatric specialist, not a telehealth intake — see what makes a prescription legitimate.
5. What happens to eating behavior? Our eating disorders article covers screening, which matters more in adolescence than at any other age.